(70 days)
Not Found
No
The description focuses on the mechanical function of biopsy forceps and does not mention any AI/ML components or capabilities.
No
The device is described as biopsy forceps, intended to obtain tissue specimens for diagnosis. It is a diagnostic tool, not one that treats or provides therapy directly.
No
The device is a biopsy forceps, which is used to obtain tissue samples for diagnosis. The device itself is not performing the diagnostic function, but rather providing a sample that will be analyzed diagnostically.
No
The device description clearly outlines physical components (handle, body, surgical stainless steel cutting jaws) and performance studies focus on the cutting abilities and tensile strength of these physical components, indicating it is a hardware device.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD devices are used to examine specimens outside of the body. They analyze samples like blood, urine, tissue, etc., to provide information about a person's health.
- The T-REX™ biopsy forceps are used inside the body to obtain the specimen. They are a surgical instrument used for tissue collection. The diagnosis is made after the tissue is collected and examined, likely using IVD methods, but the forceps themselves are not the diagnostic device.
The description clearly states the forceps are used to "obtain endomyocardial biopsy specimens" and are designed for "percutaneous access to the right or left ventricles of the heart in order to obtain diagnostic tissue samples." This is a procedure to collect a sample, not to perform a diagnostic test on a sample.
N/A
Intended Use / Indications for Use
The T.REX™ biopsy forceps is used to obtain endomyocardial biopsy specimens from the right or left ventricle via percutaneous arterial or venous approach.
The T-REX™ biopsy forceps are intended to obtain endomyocardial biopsy specimens. The specimens are taken for diagnosis of diseased heart tissue or for identification and monitoring of rejection factors in a transplanted heart.
Product codes (comma separated list FDA assigned to the subject device)
DWZ
Device Description
The T.REX™ forceps are designed to allow percutaneous access to the right or left ventricles of the heart in order to obtain diagnostic tissue samples. The forceps consist of three main components: a handle ergonomically designed for comfortable use, a body and surgical stainless steel cutting jaws.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
right or left ventricles of the heart
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance Testing (In Vitro)
Comparative testing of the cutting abilities of the T.REX™ forceps and the Bycep forceps was performed. This testing confirmed the T.REX™ forceps are capable of performing the intended function of biopsy forceps, which is to obtain samples of myocardium.
In Vitro Tests
Bench testing was done to show that models of the T.REX™ forceps built with the proposed design modifications continue to be safe and effective. Testing included the modified joints and the overall tensile strength of complete devices. Testing confirmed the T.REX™ forceps met its design specifications. Therefore, BSC Northwest concludes that the T.REXTM forceps are safe and effective.
Biocompatibility
A biological evaluation was performed on the T.REX™ forceps to give a high degree of assurance that the final product is safe for human use. These tests included material characterization, cytotoxicity, pyrogenicity and hemocompatibility assays conducted under Good Laboratory Practices (GLP). The blood contacting portion of the device was evaluated as a whole composite following two ethylene oxide (EtO) sterilization cycles. The T.REXTM forceps were found to be compatible with biological systems.
Sterilization
Following final packaging and labeling, finished devices are 100% EtO sterilized to achieve a sterility assurance level (SAL) of 10-6, or one nonsterile unit out of one million, Sterilization validation testing confirmed the ETO sterilization cycle is capable of delivering a minimum of 12 log reductions and confirmed a minimum Sterility Assurance Level (SAL) of 10 . The T.REX™ forceps are nonpyrogenic based on the Limulus Amebocyte Lysate (LAL) assay.
Clinical Tests
Clinical studies were not conducted on the T.REX™ forceps. The aspects of the device that relate to patient safety are: 1) cutting ability, 2) tensile strength of the devices, 3) biocompatibility of the materials in the fluid contact path and 4) device sterility. All of these aspects of the T.REX™ forceps have been tested, as described above, and results show the device to be safe and effective.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.4075 Endomyocardial biopsy device.
(a)
Identification. An endomyocardial biopsy device is a device used in a catheterization procedure to remove samples of tissue from the inner wall of the heart.(b)
Classification. Class II (performance standards).
0
h9738818
510(k) for the T•REX™ Biopsy Forceps
510(k) SUMMARY
A. Introduction
This 510(k) is for the T-REX™ biopsy forceps previously manufactured as the Bycep® biopsy forceps by Mansfield, Inc., a subsidiary of Boston Scientific Corporation. Research, development and manufacturing of the Bycep forceps has been relocated to Boston Scientific Corporation Northwest Technology Center, Inc. Several design modifications have been made to improve the performance and manufacturablility of the device. The indications for use and operation of this device remain the same.
| Submitter: | Boston Scientific Corporation Northwest Technology Center, Inc.
17425 N.E. Union Hill Road
Redmond, WA 98052 | DEC 16 1997 |
|---------------------------|--------------------------------------------------------------------------------------------------------------------|-------------|
| Contact: | Jocelyn Kersten
Phone: (425) 556-1667
Fax: (425) 558-1400 | |
| Preparation Date: | 10/06/97 | |
| Device Common Name: | Endomyocardial biopsy forceps | |
| Device Proprietary Name: | T•REX™ Biopsy Forceps | |
| Classification Name: | Device, biopsy, endomyocardial (74DWZ) (per 21 CFR 870.4875) | |
| Classification Panel: | Cardiovascular | |
| Manufacturing Facilities: | Heart Technology Manufacturing Center, Inc.
17425 N.E. Union Hill Road
Redmond, WA 98052 | |
B. Device Description
The T.REX™ forceps are designed to allow percutaneous access to the right or left ventricles of the heart in order to obtain diagnostic tissue samples. The forceps consist of three main components: a handle ergonomically designed for comfortable use, a body and surgical stainless steel cutting jaws.
C. Intended Use
The T.REX™ biopsy forceps is used to obtain endomyocardial biopsy specimens from the right or left ventricle via percutaneous arterial or venous approach.
1
Comparison to Predicate Device D.
The proposed T•REX™ forceps are substantially equivalent to the previously approved Bycep forceps. The indications for use remain the same, as well as the basic structure and operation of the device.
The following table summarizes the modifications.
| Component | Bycep® Forceps (K870186) | T-REX Forceps |
|---|---|---|
| End-Effector and Jaw Assembly | ||
| Jaws | Machined to sharpness | Proprietary sharpening method |
| Actuator links | Soft or semi-hardened stainless steel | Hardened stainless steel |
| Actuator/pull wire connection | Brazed | Laser welded |
| Housing | Single unit | Laser welded housing halves |
| Housing to outer jacket connection | Soldered | Laser welded |
| Crank length/lever angle | 2.2 mm jaws, 0.0822"; 1.8 mm jaws, 0.0427" /20° | 2.2 mm jaws, 0.0774"; 1.8 mm jaws, 0.0541" /15° |
| Attachment of actuator/actuator links and jaws/housing | Rivets | Captured by laser welded housing halves |
| Body | ||
| Pull Wire | Braided stainless steel cable | Solid stainless steel wire |
| Shape | Flexible | Flexible and pre-curved |
| Liner | No liner | Liner between outer jacket and pull wire |
| Jacket sheath | None | Jacket sheath covering the outer jacket |
| Handle assembly | ||
| Handle transition to outer jacket | Solder joint with coil strain relief around the joint | Crimped joint with integral strain relief |
| Handle transition to handle body | Brass handle transition press fit into straight handle body | Stainless steel handle transition press fit into tapered handle body |
| Finger grip/Handle body | No locking feature | Locking feature for holding jaws open during specimen removal |
| Finger grip insert for attachment of pull wire | Brass/Sonic welding | Aluminum/Press fit |
| Handle spring | None | ½" diameter spring coil |
| Package | ||
| Configuration | Double barrier | Single barrier |
| Product holder | Tray | Coil or card |
•
3
2
510(k) for the T-Rex™ Biopsy Forceps
End effector and Jaw Assembly 1.
In both the Bycep models and the T.REX™ models of the biopsy forceps, the pull wire, which translates movement of the handle into opening and closing the jaws, is attached to the jaws through the end effector assembly. The Bycep models utilize brazing, soldering and rivets to construct the necessary joints in the end effector assembly. The T.REXTM models utilize laser welding to construct these joints. The jaws of the Bycep forceps are sharpened with machining while the jaws of the T.REX™ models are sharpened using a proprietary process.
In both models, when the handle is manipulated, the force is transmitted down the pull wire to the actuator. The actuator links then translate the longitudinal force from the handle into vertical force on the jaws, which opens the jaws. When the handle is released, the jaws close. Gentle force on the thumb ring of the handle ensures the jaws remain closed tightly enough to retain a cut tissue sample.
2. Bodv
The body of the forceps consists of a hollow outer jacket which contains the pull wire. The pull wire in the Bycep models is a braided stainless steel cable. The T.REXTM models contain a solid stainless steel pull wire. The solid wire allows forming by the manufacturer to produce the pre-curved models and allows the flexible models to be formed by the customer prior to use. The outer jackets of the T-REX™ models are lined and covered by a sheath. The Bycep forceps contain no liner and are not coated.
3. Handle Assembly
The stainless steel handle transition is crimped onto the outer jacket of the T.REX™ models. The outer sheath is heat shrunk over the distal end of the handle transition to serve as an integral strain relief. The outer jacket of the Bycep models is soldered to the brass handle transition and utilizes a stainless steel coil strain relief. The handle transitions of both models are press fit into the handle bodies. The mating portion of the handle body is cylindrical in the Bycep models and reinforced by ribs in the T.REX™ model.
The handles of both the Bycep and T.REX models consist of a handle body, finger grip and thumb ring. Two fingers are placed into the finger grip and the thumb is placed in the thumb ring. The thumb is pulled back to open the jaws and released or pushed forward to close them. A spring coil within the handle of the T.REX™ models holds the jaws closed when the handle is in the neutral position. Also, a locking feature on the handle will secure the jaws in an open position to aid in removing the tissue sample from the jaws. The Bycep models do not contain the handle spring or the locking feature.
4
3
510(k) for the T-Rex™ Biopsy Forceps
In both models, the handle operates the jaws via the pull wire. The pull wire is attached to the handle at the finger grip insert. This insert allows the pull wire to be captured between an aluminum disc and the insert, and held in place by a set screw. The method of attachment is the same for both models, however, in the T-REX™ models, the finger grip insert is aluminum and is press fit into the finger grip, while in the Bycep® models, the finger grip insert is brass and is sonically welded into the finger grip.
4. Package
Both models of the forceps are provided sterile for single procedure use. The Bycep forceps are packaged in a tray contained in a double sterile barrier. The T.REX™ forceps pre-curved models are attached to a card and the flexible models are held in a plastic coil. Both the pre-curved and the flexible models are packaged in a single sterile barrier. Sterilization and packaging testing confirmed the proposed packaging will protect the product and maintain sterility.
ડ. Performance Testing (In Vitro)
Comparative testing of the cutting abilities of the T.REX™ forceps and the Bycep forceps was performed. This testing confirmed the T.REX™ forceps are capable of performing the intended function of biopsy forceps, which is to obtain samples of myocardium.
E. In Vitro Tests
Bench testing was done to show that models of the T.REX™ forceps built with the proposed design modifications continue to be safe and effective. Testing included the modified joints and the overall tensile strength of complete devices. Testing confirmed the T.REX™ forceps met its design specifications. Therefore, BSC Northwest concludes that the T.REXTM forceps are safe and effective.
F. Biocompatibility
A biological evaluation was performed on the T.REX™ forceps to give a high degree of assurance that the final product is safe for human use. These tests included material characterization, cytotoxicity, pyrogenicity and hemocompatibility assays conducted under Good Laboratory Practices (GLP). The blood contacting portion of the device was evaluated as a whole composite following two ethylene oxide (EtO) sterilization cycles. The T.REXTM forceps were found to be compatible with biological systems.
G. Sterilization
Following final packaging and labeling, finished devices are 100% EtO sterilized to achieve a sterility assurance level (SAL) of 10-6, or one nonsterile unit out of one million, Sterilization validation testing confirmed the ETO sterilization cycle is capable of delivering a minimum of 12 log reductions and confirmed a minimum Sterility Assurance Level (SAL) of 10 . The T.REX™ forceps are nonpyrogenic based on the Limulus Amebocyte Lysate (LAL) assay.
4
H. Clinical Tests
Clinical studies were not conducted on the T.REX™ forceps. The aspects of the device that relate to patient safety are: 1) cutting ability, 2) tensile strength of the devices, 3) biocompatibility of the materials in the fluid contact path and 4) device sterility. All of these aspects of the T.REX™ forceps have been tested, as described above, and results show the device to be safe and effective.
5
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with its wings spread, enclosed within a circle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged around the upper portion of the circle.
Public Health Service
Rockville MD 20857
Ms. Julie Wage Director, Requlatory Affairs Boston Scientific Corporation Northwest Technology Center, Inc. 17425 N.E. Union Hill Road Redmond, WA 98052-3376
DEC 1 6 1997
Re : K973818 T.REX™ Biopsy Forceps Requlatory Class: II (Two) Product Code: DWZ Dated: October 6, 1997 Received: October 7, 1997
Dear Ms. Wage:
We have reviewed your Section 510 (k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 A substantially equivalent determination assumes compliance to 895. with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such Failure to comply with the GMP regulation may result in assumptions. regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
6
Page 2 - Ms. Julie Wage
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html."
sincerely yours,
Thomas J. Callahan
Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
| 510(k) Number (if known): | K 1) 38 i 8 |
|---|---|
| --------------------------- | ------------- |
Device Name:
Indications For Use:
T.REX™ Biopsy Forceps Device:
The T-REX™ biopsy forceps are intended to obtain endomyocardial biopsy specimens. The specimens are taken for diagnosis of diseased heart tissue or for identification and monitoring of rejection factors in a transplanted heart.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices R9 138 510(k) Number Prescription Use OR Over-The-Counter Use (Per 21 CFR 801.109) :
(Optional Format 1-2-96)